Bisindolylmaleimide VIII (acetate)
(Synonyms: 3-[1-(3-氨基丙基)-1H-吲哚-3-基]-4-(1-甲基-1H-吲哚-3-基)-1H-吡咯-2,5-二酮单乙酸盐,BIM VIII,Ro 31-7549) 目录号 : GC13226A PKC inhibitor
Cas No.:138516-31-1
Sample solution is provided at 25 µL, 10mM.
IC50: 158 nM for rat brain PKC
Bisindolylmaleimide VIII is a protein kinase C (PKC) inhibitor.
The protein kinase C (PKC) consists of a family of closely related isoenzymes mediating various signal transduction processes. The ten isoenzymes that have been currently identified can be divided into three families on the basis of their different requirements for activation. Members of the conventional PKC family are Ca2+ and phospholipid-dependent and are activated by diacylglycerols and phorbol esters.
In vitro: Previous study found that bisindolylmaleimides carrying a straight-chain alkyl side-chain bearing a cationic substituent, such as Ro 31-7549 (bisindolylmaleimide VIII) and Ro 31-8220, showed a significant improvement in potency over the simple bisindolylmaleimides. For bisindolylmaleimide VIII, a further improvement in potency was obtained by restricting the position of the amine substituent. Moreove, unlike the indolocarbazole, staurosporine, which displayed 2-fold selectivity for PKC-β over the other examined isoenzymes, bisindolylmaleimide VIII exhibited a slight selectivity for PKC-α over the other isoenzymes. Compounds such as bisindolylmaleimide VIII carrying a straight-chain alkyl side-chain with the cationic substituent were found to be equipotent as inhibitors of PKC-β, PKC-γ and PKC-ε [1].
In vivo: Animal study found that, in neonatal rats, high glucose levels could induce the hypertrophy of cardiomyocytes. Ro-31-8220, a analog of bisindolylmaleimide VIII, was able to reverse the effect of high glucose on the cardiac myocytes,which might be through PKC/NF-κB/c-Fos pathway [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Wilkinson, S. E.,Parker, P.J. and Nixon, J.S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochemistry Journal 294, 335-337 (1993).
[2] Zhang, W. B. et al. Reverse effect of protein kinase C inhibitor Ro-31-8220 on the hypertrophy of cardiomyocytes of neonatal rats induced by high glucose levels. Chinese Journal of Pathophysiology. 2009-08.
Cas No. | 138516-31-1 | SDF | |
别名 | 3-[1-(3-氨基丙基)-1H-吲哚-3-基]-4-(1-甲基-1H-吲哚-3-基)-1H-吡咯-2,5-二酮单乙酸盐,BIM VIII,Ro 31-7549 | ||
化学名 | 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, acetate | ||
Canonical SMILES | O=C(N1[H])C(C2=CN(C)C3=C2C=CC=C3)=C(C4=CN(CCCN)C5=C4C=CC=C5)C1=O.CC(O)=O | ||
分子式 | C24H22N4O2 • C2H4O2 | 分子量 | 458.5 |
溶解度 | 5mg/mL in DMSO, 5mg/mL in DMF | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.181 mL | 10.9051 mL | 21.8103 mL |
5 mM | 0.4362 mL | 2.181 mL | 4.3621 mL |
10 mM | 0.2181 mL | 1.0905 mL | 2.181 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet